专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5066678A Phenethandamine derivatives and pharmaceutical use thereof 失效
标题翻译：苯并咪唑衍生物及其药物用途
公开(公告)号：US5066678A
公开(公告)日：1991-11-19
申请号：US512874
申请日：1990-04-23
申请人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell , Charles Willbe , William L. Mitchell , Stephen Swanson , Brian D. Judkins
发明人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell , Charles Willbe , William L. Mitchell , Stephen Swanson , Brian D. Judkins
IPC分类号： C07C307/06 , A61K31/135 , A61K31/18 , C07C213/00 , C07C217/08 , C07C217/46 , C07C233/36 , C07C233/43 , C07C275/10 , C07C275/14 , C07C311/04 , C07C311/08 , C07C311/35
CPC分类号： C07C217/08 , C07C311/35 , C07C2101/08 , C07C2101/14
摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof; wherein;R.sup.1 and R.sup.2 each independently represent a hydrogen atom or a C.sub.1-3 -alkyl group with the proviso that the sum total of carbon atom in R.sup.1 and R.sup.2 is not more than 4;X represents a direct bond or a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene group and Y represents a direct bond or a C.sub.1-6 alkylene C.sub.2-6 alkenylene or C.sub.2-6 alknylene group with the proviso that the sum total of carbon atoms in X and Y is not more than 10;W represents a group ##STR2## wherein Z represents a group R.sup.3 (CH.sub.2).sub.q where q is 0, 1 or 2 and R.sup.3 is a group R.sup.4 CONH--, R.sup.4 NHCONH--, R.sup.4 R.sup.5 NSO.sub.2 NH--, R.sup.6 SO.sub.2 NH-- or --OH;R.sup.4 and R.sup.5 each represent a hydrogen atom or a C.sub.1-3 alkyl group;R.sup.6 represents a C.sub.1-3 alkyl group;R.sup.7 represents a chlorine atom or the group --CF.sub.3 ;A represents a straight or branched C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, either of which may be saturated or unsaturated, or a C.sub.1-6 alkoxy group, with the proviso that the sum total of carbon atoms in A and Y is not less than 5;having a stimulant action at .beta..sub.2 -adrenoreceptors and are useful in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

2. 发明授权

US4908386A Ethanolamine derivatives 失效
标题翻译：乙醇胺衍生物
公开(公告)号：US4908386A
公开(公告)日：1990-03-13
申请号：US287441
申请日：1988-12-20
申请人： Harry Finch , Lawrence H. C. Lunts , Alan Naylor , Ian F. Skidmore , Ian B. Campbell , David Middlemiss , Charles Willbe
发明人： Harry Finch , Lawrence H. C. Lunts , Alan Naylor , Ian F. Skidmore , Ian B. Campbell , David Middlemiss , Charles Willbe
IPC分类号： C07D213/65 , C07D295/096 , C07C143/74 , A61K31/18
CPC分类号： C07D295/096 , C07D213/65 , Y10S514/826
摘要： The present invention provides compounds of general formula (I) ##STR1## wherein Ar represents an unsubstituted or substituted phenyl gorup;R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-3 alkyl group;X represents a bond or a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene chain;Y represents a bond or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain;Q represents a substituted phenyl or pyridyl ring;and physiologically acceptable salts and solvates thereof useful as stimulants of .sub.2 -adrenoreceptors and particularly in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.
摘要翻译：本发明提供通式（I）的化合物，其中Ar表示未取代或取代的苯基; R1和R2各自表示氢原子或C1-3烷基; X表示键或C 1-7亚烷基，C 2-7亚烯基或C 2-7亚炔基链; Y表示键或C 1-6亚烷基，C 2-6亚烯基或C 2-6亚炔基链; Q表示取代的苯基或吡啶环; 以及其可用作2-肾上腺素受体的兴奋剂的生理上可接受的盐和溶剂合物，特别是用于治疗与可逆气道阻塞如哮喘和慢性支气管炎相关的疾病。

3. 发明授权

US4853382A Aminophenol derivatives 失效
标题翻译：氨基苯酚衍生物
公开(公告)号：US4853382A
公开(公告)日：1989-08-01
申请号：US124601
申请日：1987-11-24
申请人： Ian F. Skidmore , Harry Finch , Alan Naylor , Lawrence H. C. Lunts , Ian B. Campbell
发明人： Ian F. Skidmore , Harry Finch , Alan Naylor , Lawrence H. C. Lunts , Ian B. Campbell
IPC分类号： A61K31/165 , A61K31/17 , A61K31/195 , A61K31/215 , A61K31/22 , A61K31/235 , A61K31/27 , A61K31/275 , A61K31/335 , A61K31/357 , A61K31/445 , A61K31/535 , A61K31/5375 , A61K31/54 , A61P11/08 , A61P25/02 , C07C67/00 , C07C231/00 , C07C233/43 , C07C233/78 , C07C253/00 , C07C255/37 , C07C255/54 , C07C275/24 , C07C275/32 , C07C275/40 , C07C301/00 , C07C303/40 , C07C307/10 , C07C311/00 , C07C313/00 , C07C315/04 , C07C317/18 , C07D295/08 , C07D317/54 , C07D319/18
CPC分类号： C07C275/40
摘要： The invention provides compounds of the general formula (I) ##STR1## wherein Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms, or the groups C.sub.1-6 alkyl, C.sub.1-6 alkoxy, nitro, --(CH.sub.2).sub.q R, [where R is hydroxy, --NR.sup.3 R.sup.4 (where R.sup.3 and R.sup.4 each represents a hydrogen atom, or a C.sub.1-4 alkyl group, or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--), --NR.sup.5 COR.sup.6 (where R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or --NR.sup.3 R.sup.4 group), --NR.sup.5 SO.sub.2 R.sup.7 (where R.sup.7 represents a C.sub.1-4 alkyl, phenyl or --NR.sup.3 R.sup.4 group), --COR.sup. 8 (where R.sup.8 represents hydroxy, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4), --SR.sup.9 (where R.sup.9 is a hydrogen atom, or a C.sub.1-4 alkyl or phenyl group), --SOR.sup.9, --SO.sub.2 R.sup.9, or --CN, and q represents an integer from 0 to 3], --(CH.sub.2).sub.r R.sup.10, [where R.sup.10 is a C.sub.1-4 alkoxy group and r represents an integer from 1 to 3] or --O(CH.sub.2).sub.t R.sup.11 [where R.sup.11 represents a hydroxy or C.sub.1-4 alkoxy group and t is 2 or 3] or Ar is a phenyl group substituted by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O--, where p represents 1 or 2;R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;X represents a C.sub.1-7 alkylene, C.sub.2-7 alkylene or C.sub.2-7 alkynylene chain;Y represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is 2 to 10;Q represents a group R.sup.12 CO--, R.sup.12 NHCO--, R.sup.12 R.sup.13 NSO.sub.2 -- or R.sup.14 SO.sub.2, where R.sup.12 and R.sup.13 each represent a hydrogen atom or a C.sub.1-3 alkyl group, and R.sup.14 represents a C.sub.1-4 alkyl group, with the proviso that when X represents C.sub.1-7 alkylene, and Y represents a bond or C.sub.1-6 alkylene, then the group Ar does not represent an unsubstituted phenyl group or a phenyl group substituted by one or more substituents selected solely from halogen atoms or C.sub.1-6 alkyl or C.sub.1-6 alkoxy groups or an alkylenedioxy group --O(CH.sub.2).sub.p O--;and physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used, inter alia, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

4. 发明授权

US4943591A Dichloroaniline derivatives 失效
公开(公告)号：US4943591A
公开(公告)日：1990-07-24
申请号：US918317
申请日：1986-10-14
申请人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell
发明人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell
IPC分类号： C07C45/00 , C07D295/096 , C07D295/192
CPC分类号： C07D295/192 , C07C45/004 , C07D295/096 , Y10S514/826
摘要： The invention provides compounds of the general formula (I) ##STR1## wherein X represents a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain andY represents a bond, or a C.sub.1-4 alkylene, C.sub.2-4 alkenylene or C.sub.2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8;Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups C.sub.1-3 alkyl, nitro, --(CH.sub.2).sub.q R [where R is hydroxy, C.sub.1-3 alkoxy, --NR.sup.3 R.sup.4 (where R.sup.3 and R.sup.4 each represent a hydrogen atom, or a C.sub.1-4 alkyl group, or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--), --NR.sup.5 COR.sup.6 (where R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4 group), and q represents an integer from 0 to 3], --NR.sup.5 COR.sup.19 (where R.sup.5 is as defined above and R.sup.19 represents a phenyl group), --(CH.sub.2).sub.r R.sup.7 [where R.sup.7 represents --NR.sup.5 SO.sub.2 R.sup.8 (where R.sup.8 represents a C.sub.1-4 alkyl, phenyl or --NR.sup.3 R.sup.4 group), --NR.sup.5 COCH.sub.2 N(R.sup.5).sub.2 (where each of the groups R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group), --COR.sup.9 (where R.sup.9 represents hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), --SR.sup.10 (where R.sup.10 is a hydrogen atom, or a C.sub.1-4 alkyl group optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), --SOR.sup.10, --SO.sub.2 R.sup.10, --CN, or --NR.sup.11 R.sup.12 (where R.sup.11 and R.sup.12 represent a hydrogen atom or a C.sub.1-4 alkyl group, at least one of which is C.sub.2-4 alkyl substituted by a hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), and r represents an integer from 0 to 3], --O(CH.sub.2).sub.q COR.sup.9 (where q and R.sup.9 are as defined above), or --O(CH.sub.2).sub.t R.sup.13 [where R.sup.13 represents hydroxy, NR.sup.3 R.sup.4, NR.sup.11 R.sup.12 or a C.sub.1-4 alkoxy group optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4, and t is an integer 2 or 3], or Ar is a phenyl group substituted by an alkylenedioxy group --O(CH.sub.2).sub.p O-- where p is 1 or 2;R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-3 alkyl group, with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds of formula (I) have a stimulant action at .beta..sub.2 -adrenoreceptors and are useful, in particular, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

5. 发明授权

US5006556A Dichloroaniline derivatives for the therapy or prophylaxysis of a disease associated with reversible airway obstruction 失效
标题翻译：用于治疗或预防与可逆性气道阻塞相关的疾病的二氯苯胺衍生物
公开(公告)号：US5006556A
公开(公告)日：1991-04-09
申请号：US524141
申请日：1990-05-15
申请人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell
发明人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell
IPC分类号： C07C45/00 , C07D295/096 , C07D295/192
CPC分类号： C07D295/192 , C07C45/004 , C07D295/096 , Y10S514/826
摘要： The invention provides compounds of the general formula (I) ##STR1## wherein X represents a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain andY represents a bond, or a C.sub.1-4 alkylene, C.sub.2-4 alkenylene or C.sub.2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8;Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups C.sub.1-3 alkyl, nitro, --(CH.sub.2)qR [where R is hydroxy, C.sub.1-3 alkoxy, --NR.sup.3 R.sup.4 (where R.sup.3 and R.sup.4 each represent a hydrogen atom, or a C.sub.1-4 alkyl group, or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--), --NR.sup.5 COR.sup.6 (where R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4 group), and q represents an integer from 0 to 3], --NR.sup.5 COR.sup.19 (where R.sup.5 is as defined above and R.sup.19 represents a phenyl group), --(CH.sub.2).sub.r R.sup.7 [where R.sup.7 represents --NR.sup.5 SO.sub.2 R.sup.8 (where R.sup.8 represents a C.sub.1-4 alkyl, phenyl or --NR.sup.3 R.sup.4 group), --NR.sup.5 COCH.sub.2 N(R.sup.5).sub.2 (where each of the groups R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group), --COR.sup.9 (where R.sup.9 represents hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), --SR.sup.10 (where R.sup.10 is a hydrogen atom, or a C.sub.1-4 alkyl group optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), --SOR.sup.10, --SO.sub.2 R.sup.10, --CN, or --NR.sup.11 R.sup.12 (where R.sup.11 and R.sup.12 represent a hydrogen atom or a C.sub.1-4 alkyl group, at least one of which is C.sub.2-4 alkyl substituted by a hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4 group), and r represents an integer from 0 to 3], --O(CH.sub.2).sub.q COR.sup.9 (where q and R.sup.9 are as defined above), or --O(CH.sub.2).sub.t R.sup.13 [where R.sup.13 represents hydroxy, NR.sup.3 R.sup.4, NR.sup.11 R.sup.12 or a C.sub.1-4 alkoxy group optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4, and t is an integer 2 or 3], or Ar is a phenyl group substituted by an alkylenedioxy group --O(CH.sub.2).sub.p O-- where p is 1 or 2; R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-3 alkyl group, with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds of formula (I) have a stimulant action at .beta..sub.2 -adrenoreceptors and are useful, in particular, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

6. 发明授权

US4990505A Phenethanolamine compounds 失效
标题翻译：苯乙醇胺化合物
公开(公告)号：US4990505A
公开(公告)日：1991-02-05
申请号：US339688
申请日：1989-04-18
申请人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell
发明人： Ian F. Skidmore , Lawrence H. C. Lunts , Harry Finch , Alan Naylor , Ian B. Campbell
IPC分类号： A61K31/13 , A61K31/135 , A61K31/395 , A61K31/55 , C07C43/23 , C07C45/00 , C07C45/68 , C07C47/575 , C07C49/255 , C07C65/21 , C07C205/34 , C07C311/02 , C07C311/15 , C07C317/00 , C07D295/04 , C07D295/096 , C07D295/12 , C07D317/54
CPC分类号： C07D295/096 , C07C205/34 , C07C317/00 , C07C323/00 , C07C45/00 , C07C45/68 , C07C47/575 , C07C49/255 , C07C65/21 , C07D317/54
摘要： The invention provides compounds of the general formula (I) ##STR1## wherein the substituents are defined in the specification, and physiologically acceptable salts and solvates thereof.The compounds of formula (I) have a selective stimulant action at .beta..sub.2 -adrenoreceptors and are useful, in particular in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.
摘要翻译：本发明提供了通式（I）的化合物，其中取代基在说明书中定义，以及其生理上可接受的盐和溶剂化物。式（I）化合物在β2-肾上腺素受体中具有选择性刺激作用，并且特别用于治疗与可逆气道阻塞如哮喘和慢性支气管炎相关的疾病。

7. 发明授权

US4963564A Phenethanolamine derivatives 失效
标题翻译：苯乙醇胺衍生物
公开(公告)号：US4963564A
公开(公告)日：1990-10-16
申请号：US230359
申请日：1988-08-10
申请人： Ian F. Skidmore , Alan Naylor , Harry Finch , Lawrence H. C. Lunts , Ian B. Campbell
发明人： Ian F. Skidmore , Alan Naylor , Harry Finch , Lawrence H. C. Lunts , Ian B. Campbell
IPC分类号： A61K31/40 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/425 , A61K31/426 , A61K31/428 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/535 , A61K31/5355 , A61K31/5377 , A61P1/04 , A61P9/00 , A61P11/00 , A61P13/02 , A61P15/00 , A61P25/02 , A61P25/24 , A61P25/26 , A61P27/02 , A61P27/14 , A61P29/00 , A61P37/08 , C07D213/30 , C07D213/65 , C07D215/14 , C07D235/12 , C07D239/26 , C07D241/12 , C07D251/02 , C07D263/56 , C07D277/24 , C07D277/64
CPC分类号： C07D213/30 , C07D213/65 , C07D215/14
摘要： The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, wherein Z represents the group ##STR2## (wherein Q.sup.1 represents a straight or branched C.sub.1-3 alkylene group), ##STR3## (where Q.sup.2 represents a group R.sup.5 CO--, R.sup.5 NHCO--, R.sup.5 R.sup.6 NSO.sub.2 -- or R.sup.7 SO.sub.2 --, where R.sup.5 and R.sup.6 each represent a hydrogen atom or a C.sub.1-3 alkyl group, and R.sup.7 represents a C.sub.1-3 alkyl group), or ##STR4## X represents a bond, or a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene chain, and Y represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain with the proviso that the sum total of carbon atoms in the chains X and Y is not more than 10;R represents a hydrogen atom or C.sub.1-3 alkyl group;R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group; with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; andHet represents a benzoheteroaryl or a monocyclic heteroaryl group wherein the heteroaryl group is 5 or 6 membered and contains 1, 2 or 3 hetero atoms, one of which is a nitrogen atom and the other(s) is (are) nitrogen, oxygen or sulphur atom(s), and the group Het may optionally be substituted by one or two groups selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, halogen, --NR.sup.3 R.sup.4 and --COR.sup.8 ; where R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--; andR.sup.8 represents hydroxy, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4.The compounds have a stimulant action at .beta.2-adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

8. 发明授权

US4730008A Aminophenol derivatives 失效
标题翻译：氨基苯酚衍生物
公开(公告)号：US4730008A
公开(公告)日：1988-03-08
申请号：US817676
申请日：1986-01-10
申请人： Ian F. Skidmore , Harry Finch , Alan Naylor , Lawrence H. C. Lunts , Ian B. Campbell
发明人： Ian F. Skidmore , Harry Finch , Alan Naylor , Lawrence H. C. Lunts , Ian B. Campbell
IPC分类号： A61K31/165 , A61K31/17 , A61K31/195 , A61K31/215 , A61K31/22 , A61K31/235 , A61K31/27 , A61K31/275 , A61K31/335 , A61K31/357 , A61K31/445 , A61K31/535 , A61K31/5375 , A61K31/54 , A61P11/08 , A61P25/02 , C07C67/00 , C07C231/00 , C07C233/43 , C07C233/78 , C07C253/00 , C07C255/37 , C07C255/54 , C07C275/24 , C07C275/32 , C07C275/40 , C07C301/00 , C07C303/40 , C07C307/10 , C07C311/00 , C07C313/00 , C07C315/04 , C07C317/18 , C07D295/08 , C07D317/54 , C07D319/18 , C07C143/74 , A61K31/18
CPC分类号： C07C275/40
摘要： The invention provides compounds of the general formula (I) ##STR1## wherein Ar, R.sup.1, R.sup.2, X, Y and Q are defined in the specification and physiologically acceptable salts and solvates thereof.The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used, inter alia, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.
摘要翻译：本发明提供通式（I）的化合物其中Ar，R 1，R 2，X，Y和Q在本说明书及其生理上可接受的盐和溶剂合物中定义。这些化合物在β2-肾上腺素受体具有选择性刺激作用，并且可以用于治疗与可逆性气道阻塞如哮喘和慢性支气管炎相关的疾病。

9. 发明授权

US4990664A Ethanolamine derivatives 失效
公开(公告)号：US4990664A
公开(公告)日：1991-02-05
申请号：US230357
申请日：1988-08-10
申请人： Ian F. Skidmore , Alan Naylor , Harry Finch , Lawrence H. C. Lunts , Ian B. Campbell , Peter C. North
发明人： Ian F. Skidmore , Alan Naylor , Harry Finch , Lawrence H. C. Lunts , Ian B. Campbell , Peter C. North
IPC分类号： C07D295/18 , A61K31/135 , A61K31/165 , A61K31/18 , A61K31/44 , A61K31/4402 , A61K31/4418 , A61K31/47 , A61P5/38 , C07C67/00 , C07C231/00 , C07C237/30 , C07C301/00 , C07C303/34 , C07C309/66 , C07C313/00 , C07C323/25 , C07C323/27 , C07C323/41 , C07C323/42 , C07C323/43 , C07C323/44 , C07C323/49 , C07C323/60 , C07C323/62 , C07C323/65 , C07C325/00 , C07D213/32 , C07D213/65 , C07D215/26
CPC分类号： C07C323/62 , C07C323/25 , C07D213/32
摘要： The invention provides compounds of the general formula ##STR1## and physiologically acceptable salts and solvates thereof, wherein Z represents the group ##STR2## where A represents a group selected from HOR.sup.3 --, R.sup.6 NH(CH.sub.2)p--, R.sup.10 R.sup.11 N--, R.sup.12 OCH.sub.2 --, CH.sub.3 SO.sub.2 CH.sub.2 -- or NCCH.sub.2 --;where R.sup.3 is a C.sub.1-3 alkylene group,R.sup.6 is a group selected from R.sup.7 CO--, R.sup.7 NHCO--, R.sup.7 R.sup.8 NSO.sub.2 -- orR.sup.9 SO.sub.2 --, and p is zero or 1,R.sup.7 and R.sup.8 each represent a hydrogen atom or a C.sub.1-3 alkyl group,R.sup.9 is a C.sub.1-3 alkyl group,R.sup.10 and R.sup.11 each represent a hydrogen atom or a C.sub.1-4 alkyl group or, when R.sup.10 is a hydrogen atom, R.sup.11 may also be a C.sub.1-4 alkoxycarbonyl group, andR.sup.12 is a C.sub.1-3 alkyl group; ##STR3## where one of R.sup.4 and R.sup.5 is a hydroxy group and the other is a hydrogen or halogen atom or a hydroxy group; ##STR4## where A.sup.1 is either a chlorine atom or a --CF.sub.3 group; ##STR5## X represents a bond or a C.sub.1-7 alkenylene or C.sub.2-7 alkynylene chain, andY represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain, with the proviso that the sum total of carbon atoms in X and Y is 2 to 10;R represents a hydrogen atom or a C.sub.1-3 alkyl group;R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-3 alkyl group; with the proviso that the sum total of carbon atoms inR.sup.1 and R.sup.2 is not more than 4;Q represents a pyridyl group optionally substituted by one or two substituents selected from halogen atoms or hydroxy, C.sub.1-3 alkyl or C.sub.1-3 alkoxy groups, or Q represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups C.sub.1-6 alkyl, nitro, --(CH.sub.2).sub.q R.sup.13 or --O(CH.sub.2).sub.r R.sup.14, or Q represents a phenyl group substituted by an alkylenedioxy group of formula --O(CH.sub.2).sub.t O--; whereR.sup.13 represents hydroxy, C.sub.1-6 alkoxy, cyano, --NR.sup.15 R.sup.16, --NR.sup.17 COR.sup.18, --NR.sup.17 SO.sub.2 R.sup.19, --COR.sup.20, --SR.sup.21, --SOR.sup.22 or --SO.sub.2 R.sup.22 ;R.sup.14 represents hydroxy or C.sub.1-4 alkoxy;R.sup.15 and R.sup.16 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.15 R.sup.16 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--;R.sup.17 represents a hydrogen atom or a C.sub.1-4 alkyl group;R.sup.18 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or --NR.sup.15 R.sup.16 group;R.sup.19 represents C.sub.1-4 alkyl, phenyl or --NR.sup.15 R.sup.16 ;R.sup.20 represents hydroxy, C.sub.1-4 alkoxy or --NR.sup.15 R.sup.16 ;R.sup.21 represents a hydrogen atom or a C.sub.1-4 alkyl or phenyl group;R.sup.22 represents a C.sub.1-4 alkyl or phenyl group;q represents an integer from 0 to 3;r represents 2 or 3; andt represents 1 or 2.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

10. 发明授权

US4959381A Pyridine compounds which have useful activity associated with reversible air ways obstruction 失效
标题翻译：具有与可逆气道阻塞相关的有用活性的吡啶化合物
公开(公告)号：US4959381A
公开(公告)日：1990-09-25
申请号：US153939
申请日：1988-02-09
申请人： Lawrence H. C. Lunts , Ian F. Skidmore , Harry Finch , Alan Naylor , Ian B. Campbell
发明人： Lawrence H. C. Lunts , Ian F. Skidmore , Harry Finch , Alan Naylor , Ian B. Campbell
IPC分类号： A61K31/44 , A61K31/4402 , A61K31/4418 , A61P1/04 , A61P9/00 , A61P11/08 , A61P13/02 , A61P15/00 , A61P17/00 , A61P25/24 , A61P25/26 , A61P27/02 , A61P27/14 , A61P37/08 , C07C67/00 , C07C213/00 , C07C217/10 , C07C217/76 , C07C231/00 , C07C231/12 , C07C233/25 , C07C233/75 , C07C239/00 , C07C275/32 , C07D213/30 , C07D213/61 , C07D213/62 , C07D213/69
CPC分类号： C07D213/30
摘要： The present invention provides compounds of the general formula (I) ##STR1## wherein X represents a bond, or a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain, andY represents a bond, or a C.sub.1-4 alkylene, C.sub.2-4 alkenylene or C.sub.2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8;R.sup.1 and R.sup.2 each represent a hydrogen atom or a C.sub.1-3 alkyl group, with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; andAr represents a pyridyl group optionally substituted by one or two substituents selected from halogen atoms or hydroxy, C.sub.1-3 alkyl and C.sub.1-3 alkoxy groups, orAr represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups hydroxy, hydroxyC.sub.1-3 alkyl, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, --NR.sup.3 R.sup.4 and --NR.sup.5 COR.sup.6,or Ar is a phenyl group substituted by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O--; whereR.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-4 alkyl group or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- and --S-- or a group --NH-- or --N(CH.sub.3)--;R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group; R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl or --NR.sup.3 R.sup.4 group;p is an integer 1 or 2;and physiologically acceptable salts and solvates (e.g. hydrates) thereof.The compounds have a stimulant action at .beta.-adreno receptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式